Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

Index by author

January 2009; Volume 50,Issue 1

Cover image

Cover image expansion

In non-Hodgkin lymphoma, 18F-FDG uptake in tumors typically drops after radioimmunotherapy, with the largest declines occurring in those with the longest progression-free survival. This patient, whose baseline PET/CT scan (top) and follow-up scans at 12 wk (middle) and 24 wk (bottom) showed a gradual decline in the size and metabolic activity of lymph nodes, remained without evidence of active disease 28 mo after radioimmunotherapy.
See page 8.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 50 (1)
Journal of Nuclear Medicine
Vol. 50, Issue 1
January 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Sign up for alerts

Jump to

  • This Month in JNM
  • SNM Newsline
  • Focus on Molecular Imaging
  • Comments and Perspectives
  • Invited Perspectives
  • Clinical Investigations
  • Continuing Education
  • Erratum
  • Basic Science Investigations
  • Special Contributions
  • Letters to the Editor
  • Book Reviews
  • Most Cited
  • Most Read
Loading
  • First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
  • Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from 18F-FDG PET Imaging and Neuronal Autoantibodies
  • Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
  • Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View
  • Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
More...
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire